SG10201600179RA - Processes for preparing isoquinolinones and solid forms of isoquinolinones - Google Patents

Processes for preparing isoquinolinones and solid forms of isoquinolinones

Info

Publication number
SG10201600179RA
SG10201600179RA SG10201600179RA SG10201600179RA SG10201600179RA SG 10201600179R A SG10201600179R A SG 10201600179RA SG 10201600179R A SG10201600179R A SG 10201600179RA SG 10201600179R A SG10201600179R A SG 10201600179RA SG 10201600179R A SG10201600179R A SG 10201600179RA
Authority
SG
Singapore
Prior art keywords
isoquinolinones
processes
preparing
solid forms
solid
Prior art date
Application number
SG10201600179RA
Inventor
Pingda Ren
Michael Martin
Paul Isbester
Benjamin S Lane
Jason Kropp
Original Assignee
Infinity Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46491229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201600179R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Infinity Pharmaceuticals Inc filed Critical Infinity Pharmaceuticals Inc
Publication of SG10201600179RA publication Critical patent/SG10201600179RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201600179RA 2011-01-10 2012-01-10 Processes for preparing isoquinolinones and solid forms of isoquinolinones SG10201600179RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161431304P 2011-01-10 2011-01-10
US201161578655P 2011-12-21 2011-12-21

Publications (1)

Publication Number Publication Date
SG10201600179RA true SG10201600179RA (en) 2016-02-26

Family

ID=46491229

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013052568A SG191897A1 (en) 2011-01-10 2012-01-10 Processes for preparing isoquinolinones and solid forms of isoquinolinones
SG10201600179RA SG10201600179RA (en) 2011-01-10 2012-01-10 Processes for preparing isoquinolinones and solid forms of isoquinolinones

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013052568A SG191897A1 (en) 2011-01-10 2012-01-10 Processes for preparing isoquinolinones and solid forms of isoquinolinones

Country Status (23)

Country Link
US (7) US8809349B2 (en)
EP (3) EP3238722B1 (en)
JP (2) JP2014501790A (en)
KR (2) KR20180080358A (en)
CN (1) CN103648499B (en)
AR (1) AR084824A1 (en)
AU (1) AU2012205669B2 (en)
BR (1) BR112013017670B1 (en)
CA (1) CA2824197C (en)
CL (1) CL2013002007A1 (en)
DK (1) DK2663309T3 (en)
ES (1) ES2637113T3 (en)
HK (1) HK1245110B (en)
IL (1) IL227387B (en)
MX (1) MX347708B (en)
NZ (1) NZ612909A (en)
PE (2) PE20180318A1 (en)
PH (1) PH12018500960A1 (en)
SG (2) SG191897A1 (en)
TW (3) TWI674262B (en)
UA (1) UA115767C2 (en)
WO (1) WO2012097000A1 (en)
ZA (1) ZA201305150B (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1583562E (en) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, related compounds, and uses thereof
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR101897881B1 (en) 2008-01-04 2018-09-12 인텔리카인, 엘엘씨 Certain chemical entities, compositions and methods
EP2279008B1 (en) 2008-04-18 2019-03-06 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
JP2012505637A (en) 2008-10-15 2012-03-08 アンジオケム,インコーポレーテッド GLP-1 agonist conjugates and uses thereof
AU2009304505A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
CN102307904A (en) 2008-12-05 2012-01-04 安吉奥开米公司 Conjugates of neurotensin or neurotensin analogs and uses thereof
US9040508B2 (en) 2008-12-08 2015-05-26 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
CN102300987A (en) 2008-12-17 2011-12-28 安吉奥开米公司 Membrane Type-1 Matrix Metalloprotein Inhibitors And Uses Thereof
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
JP5789252B2 (en) 2009-05-07 2015-10-07 インテリカイン, エルエルシー Heterocyclic compounds and uses thereof
PL2448938T3 (en) 2009-06-29 2014-11-28 Incyte Holdings Corp Pyrimidinones as pi3k inhibitors
RU2012103240A (en) 2009-07-02 2013-08-10 Ангиокем Инк. MULTI-DIMENSIONAL PEPTIDE CONJUGATES AND THEIR APPLICATION
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP5961187B2 (en) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation N- (1- (substituted phenyl) ethyl) -9H-purin-6-amine as a PI3K inhibitor
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
CN103930422A (en) 2011-07-19 2014-07-16 无限药品股份有限公司 Heterocyclic compounds and uses thereof
JP6027611B2 (en) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ, インコーポレイテッド Heterocyclic compounds and uses thereof
AU2012294202B2 (en) * 2011-08-11 2017-02-23 Takeda Pharmaceutical Company Limited Kinase inhibitor polymorphs
AU2012302197B2 (en) 2011-08-29 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclylamines as pi3k inhibitors
BR112014014327A2 (en) 2011-12-15 2017-06-13 Novartis Ag use of pi3k activity or function inhibitors
AR090548A1 (en) 2012-04-02 2014-11-19 Incyte Corp BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) * 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN102850271A (en) * 2012-09-10 2013-01-02 盛世泰科生物医药技术(苏州)有限公司 Synthesis of 3-(1-aminoethyl)-2-cyclobutyl-2-hydro-isoquinolin-1-one compound
RS58023B2 (en) * 2012-11-01 2021-12-31 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US20140120060A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
JP6434416B2 (en) 2012-11-08 2018-12-05 ライゼン・ファーマシューティカルズ・エスアー Pharmaceutical composition comprising a PDE4 inhibitor and a PI3δ inhibitor or a dual PI3δ-γ kinase inhibitor
CA2895782C (en) 2012-12-21 2017-08-22 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
WO2014100767A1 (en) 2012-12-21 2014-06-26 Gilead Calistoga Llc Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
AU2014273946B2 (en) * 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
JOP20200296A1 (en) * 2013-06-10 2017-06-16 Amgen Inc Processes of Making and Crystalline Forms of a MDM2 Inhibitor
NZ714710A (en) 2013-06-14 2016-11-25 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
JP6466924B2 (en) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ, インコーポレイテッド Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) * 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN105979948A (en) 2013-12-05 2016-09-28 安塞塔制药公司 Therapeutic combination of a pi3k inhibitor and a btk inhibitor
CN104817559B (en) 2014-01-30 2021-05-25 苏州泽璟生物制药股份有限公司 Deuterated quinazolinone compound and pharmaceutical composition containing same
DK3119397T3 (en) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of PI3K-gamma-mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
TWI732337B (en) * 2014-06-20 2021-07-01 美商梅琳塔有限責任公司 Pharmaceutical composition and use thereof
AU2015283671B2 (en) 2014-07-04 2018-07-05 Lupin Limited Quinolizinone derivatives as Pl3K inhibitors
WO2016024228A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
HRP20211813T1 (en) 2014-08-11 2022-03-04 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
TW201618773A (en) 2014-08-11 2016-06-01 艾森塔製藥公司 Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a CDK4/6 inhibitor
KR20170044203A (en) 2014-09-03 2017-04-24 리젠 파마슈티컬스 소시에떼 아노님 Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid
EP3193874A4 (en) * 2014-09-17 2018-04-25 Mundipharma International Corporation Limited Crystalline forms of tyrosine kinase inhibitors and their salts
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3272751A4 (en) * 2015-02-12 2018-07-11 Crystal Pharmatech Co. Ltd. Crystal form of ipi-145 and preparation method thereof
AU2016222556B2 (en) 2015-02-27 2020-08-27 Incyte Holdings Corporation Salts of Pl3K inhibitor and processes for their preparation
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
ES2826827T3 (en) 2015-06-15 2021-05-19 Angiochem Inc Methods for the treatment of leptomeningeal carcinomatosis
KR20180058741A (en) 2015-09-14 2018-06-01 인피니티 파마슈티칼스, 인코포레이티드 Solid form of isoquinolines, a process for their preparation, compositions comprising them and methods for using them
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
PL3665179T3 (en) 2017-08-09 2021-11-29 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
KR20200091394A (en) * 2017-09-27 2020-07-30 페도라 파마슈티칼스 인코포레이티드 Pharmaceutical Form of Diazabicyclooctane Derivative and Method for Producing the Same
WO2019139399A1 (en) * 2018-01-12 2019-07-18 보령제약 주식회사 Pharmaceutical composition comprising pi3 kinase inhibitor and cytotoxic anti-cancer agent for preventing or treating cancer
CN108982465B (en) * 2018-06-06 2020-10-02 上海应用技术大学 High-flux SERS (surface enhanced Raman Scattering) online detection method for sulfur dioxide in wine
CN109364601B (en) * 2018-12-21 2021-05-28 山东京博众诚清洁能源有限公司 Method for treating refinery waste gas
KR20200129705A (en) * 2019-05-09 2020-11-18 보령제약 주식회사 PI3K Inhibitor of Amorphous and Pharmaceutical Composition Comprising the same
KR20200129704A (en) * 2019-05-09 2020-11-18 보령제약 주식회사 Crystal Polymorphism of PI3K Inhibitor and Method for Producing the Same
KR102338609B1 (en) * 2019-05-20 2021-12-14 보령제약 주식회사 Pyrido-pyrimidin compound and pharmaceutical composition for use in preventing or treating PI3 kinase related diseases
GB201915447D0 (en) * 2019-10-24 2019-12-11 Johnson Matthey Plc Polymorphs of avapritinib and methods of preparing the polymorphs
CN111675710B (en) * 2020-07-17 2023-08-18 上海奥萝拉医药科技有限公司 Preparation method of duloxetine
CN111635404B (en) * 2020-07-17 2023-11-07 苏州明锐医药科技有限公司 Preparation method of duloxetine
WO2022044040A1 (en) * 2020-08-25 2022-03-03 Msn Laboratories Private Limited, R&D Center Novel polymorphs of (s)-3-(1-(9h-purin-6-yl-amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2h)-one
CN112595691A (en) * 2020-11-16 2021-04-02 伊犁紫苏丽人生物科技有限公司 Establishment method and quantitative analysis method of lavender essential oil characteristic component quantitative analysis model based on near-infrared Raman spectrum fusion
CN112410355B (en) * 2020-11-23 2022-03-25 昆明理工大学 Acyl-coenzyme A oxidase 2 gene RKACOX2 and application thereof
EP4356114A1 (en) * 2021-06-18 2024-04-24 Polyvalor, Limited Partnership Methods and systems for interrogating a drop of saliva using raman spectroscopy
WO2023091785A1 (en) * 2021-11-22 2023-05-25 Secura Bio, Inc. Methods for treating peripheral t-cell lymphoma

Family Cites Families (671)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB812366A (en) 1955-08-18 1959-04-22 Wellcome Found Improvements in and relating to derivatives of pyrimidine and the preparation thereof
GB937725A (en) 1960-05-11 1963-09-25 Ciba Ltd Pyrazolo[3:4-d]pyrimidines
JPS4834699B1 (en) 1968-07-03 1973-10-23
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
DE2139107A1 (en) 1971-08-04 1973-02-15 Merck Patent Gmbh N(6)-subst adenosine derivs - with coronary circulatory etc activity
JPS4834699A (en) 1971-09-08 1973-05-21
JPS5148231B2 (en) 1971-10-20 1976-12-20
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
IT1153216B (en) 1981-10-16 1987-01-14 Schering Ag PROCEDURE FOR THE PREPARATION OF CYANETHEROCYCLIC COMPOUNDS
DE3244594A1 (en) 1982-12-02 1984-06-07 Hoechst Ag, 6230 Frankfurt 1-PHENYLISOCHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THIS COMPOUND AND THE USE THEREOF
DE3406533A1 (en) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim USE OF ADENOSINE DERIVATIVES AS ANTIALLERGICA AND MEDICINAL PRODUCTS CONTAINING THEM
US5310731A (en) 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
KR890002631B1 (en) 1984-10-04 1989-07-21 몬산토 캄파니 Composition of prolonged release of biologically active somatotropin
US4795627A (en) 1984-10-18 1989-01-03 University Of Pittsburgh Tritium labelled N-mustard type compounds and a process for their production
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4656159A (en) 1984-10-31 1987-04-07 Georgetown University Galactose-C-6 nitrogen mustard compounds and their uses
JPS61109797A (en) 1984-11-01 1986-05-28 Yuki Gosei Yakuhin Kogyo Kk Labeled nucleotide and labeled polynucleotide
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
WO1990003370A1 (en) 1988-09-28 1990-04-05 Microprobe Corporation DERIVATIVES OF PYRAZOLO[3,4-d]PYRIMIDINE
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
FR2638359A1 (en) 1988-11-03 1990-05-04 Tino Dalto SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5442039A (en) 1989-07-17 1995-08-15 The Dow Chemical Company Mesogenic polycyanates and thermosets thereof
US5428125A (en) 1989-07-17 1995-06-27 The Dow Chemical Company Mesogenic polycyanates and thermosets thereof
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5763597A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. Orally active adenosine kinase inhibitors
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5795977A (en) 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
JPH04211063A (en) 1990-03-05 1992-08-03 Takeda Chem Ind Ltd Condensed tricyclic heterocyclic compound, its production, use and intermediate
GB9009542D0 (en) 1990-04-27 1990-06-20 Beecham Group Plc Novel compounds
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
GB9113137D0 (en) 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
US5563257A (en) 1990-08-20 1996-10-08 Boehringer Mannheim Gmbh Phospholipid derivatives of nucleosides
DE4026265A1 (en) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh NEW PHOSPHOLIPID DERIVATIVES OF NUCLEOSIDES, THEIR PRODUCTION AND THEIR USE AS ANTIVIRAL MEDICINAL PRODUCTS
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5561134A (en) 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
ATE147074T1 (en) 1990-09-25 1997-01-15 Rhone Poulenc Rorer Int COMPOUNDS WHICH POSSESS ANTIHYPERTENSIVE AND ANTIISCHEMIC PROPERTIES
US5652366A (en) 1990-09-25 1997-07-29 Rhone-Poulenc Rorer Pharmaceuticals Inc. DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9103839D0 (en) 1991-02-23 1991-04-10 Smithkline Beecham Plc Pharmaceuticals
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en) 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5714493A (en) 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (en) 1991-09-13 1991-09-13 Kabi Pharmacia Ab INJECTION NEEDLE ARRANGEMENT
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
MX9300141A (en) 1992-01-13 1994-07-29 Smithkline Beecham Corp NOVEL IMIDAZOLE COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
DE4204031A1 (en) 1992-02-12 1993-08-19 Boehringer Mannheim Gmbh NEW LIPID PHOSPHONIC ACID-NUCLEOSIDE CONJUGATES AND THEIR USE AS ANTIVIRAL MEDICINAL PRODUCTS
DE4204032A1 (en) 1992-02-12 1993-08-19 Boehringer Mannheim Gmbh NEW LIPONUCLEOTIDES, THEIR PRODUCTION AND THEIR USE AS ANTIVIRAL MEDICINAL PRODUCTS
EP0625982B1 (en) 1992-02-13 2002-06-12 PHARMACIA & UPJOHN COMPANY 4-oxo- and 4h-imidazo(5,1-c)(1,4)benzoxazines useful as benzodiazepine receptor-binding agents
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
WO1993018035A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
JP2737518B2 (en) 1992-03-16 1998-04-08 富士通株式会社 Cooling structure of infrared detector
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
CA2133075A1 (en) 1992-04-07 1993-10-14 Craig B. Thompson CD28 Pathway Immunoregulation
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
AU4115693A (en) 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
RU2121766C1 (en) 1992-06-19 1998-11-10 Ханивелл Инк. Infrared camera and method for reading alternations in respective resistance of passive radiation-sensitive units
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
JPH08506343A (en) 1993-02-03 1996-07-09 ジェンシア・インコーポレイテッド Adenosine kinase inhibitors containing lysofuranosyl derivatives
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
GB9308957D0 (en) 1993-04-30 1993-06-16 Cancer Res Campaign Tech Novel produgs
ES2240962T3 (en) 1993-06-04 2005-10-16 The United States Of America As Represented By The Secretary Of The Navy METHOD FOR SELECTIVELY STIMULATING THE PROLIFERATION OF CELLS T.
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5525503A (en) 1993-09-28 1996-06-11 Dana-Farber Cancer Institute, Inc. Signal transduction via CD28
AU6672794A (en) 1993-11-05 1995-05-23 Biochem Pharma Inc. Antineoplastic heteronaphthoquinones
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US6632789B1 (en) 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
DE4418690A1 (en) 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Nucleoside 5'-mono-phosphate ester(s) of glyceryl di:ether derivs.
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6312894B1 (en) 1995-04-03 2001-11-06 Epoch Pharmaceuticals, Inc. Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders
DE69609602T2 (en) 1995-04-03 2001-04-12 Novartis Ag PYRAZOLE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
DK0821671T3 (en) 1995-04-20 2001-04-23 Pfizer Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
JPH08295667A (en) 1995-04-27 1996-11-12 Takeda Chem Ind Ltd Heterocyclic compound, its production and pharmaceutical preparation
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
WO1996037777A1 (en) 1995-05-23 1996-11-28 Nelson Randall W Mass spectrometric immunoassay
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
CN1142793C (en) 1995-06-07 2004-03-24 G·D·瑟尔公司 Epoxy-steroidal aldosterone antagonist and angiotensin 2 antagonist combination therapy for treatment of congestive heart failure
KR19990022723A (en) 1995-06-07 1999-03-25 윌리암스 로저 에이 Spironolactone and angiotensin II antagonist combination therapy for the treatment of congestive heart failure
AU5982296A (en) 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angi otensin ii antagonist and spironolactone
US5665721A (en) 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
CA2224381A1 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (en) 1995-09-18 1999-06-23 株式会社資生堂 Delayed release microsphere of drug
US5763885A (en) 1995-12-19 1998-06-09 Loral Infrared & Imaging Systems, Inc. Method and apparatus for thermal gradient stabilization of microbolometer focal plane arrays
JPH09143163A (en) 1995-11-29 1997-06-03 Fuji Photo Film Co Ltd Production of nitrogen-containing heteroaromatic amides
DK0780386T3 (en) 1995-12-20 2003-02-03 Hoffmann La Roche matrix metalloprotease
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5747235A (en) 1996-01-26 1998-05-05 Eastman Kodak Company Silver halide light sensitive emulsion layer having enhanced photographic sensitivity
CH690773A5 (en) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo (2,3-d) pyrimides and their use.
DE19603576A1 (en) 1996-02-01 1997-08-07 Bayer Ag Acylated 4-amino and 4-hydrazinopyrimidines
US5914488A (en) 1996-03-05 1999-06-22 Mitsubishi Denki Kabushiki Kaisha Infrared detector
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
PT807633E (en) 1996-05-15 2003-02-28 Pfizer NEW PYRIMIDIN-4-ONES REPLACED IN 2.3, AND FUSED WITH HETEROARYL (5.6)
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
BR9711805A (en) 1996-06-20 2002-01-15 Regents The Univesity Of Texas Compounds and methods for providing pharmacologically active preparations and use
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
JP3195756B2 (en) 1996-07-04 2001-08-06 公子 吉水 Lubrication auxiliary
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
ES2175415T3 (en) 1996-07-18 2002-11-16 Pfizer PHOSPHINATE-BASED MATRIX METALOPROTEASES INHIBITORS.
EA199900139A1 (en) 1996-08-23 1999-08-26 Пфайзер, Инк. DERIVATIVES OF ARYL SULPHONYLAMINO HYDROXAMIC ACID
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
US5965573A (en) 1996-10-23 1999-10-12 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6251901B1 (en) 1996-10-23 2001-06-26 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5919808A (en) 1996-10-23 1999-07-06 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5922753A (en) 1996-10-23 1999-07-13 Zymogenetics, Inc. Methods for treating bone deficit conditions with benzothiazole
US5994358A (en) 1996-10-23 1999-11-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5948776A (en) 1996-10-23 1999-09-07 Zymogenetic, Inc. Compositions and methods for treating bone deficit conditions
US6342514B1 (en) 1996-10-23 2002-01-29 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5990169A (en) 1996-10-23 1999-11-23 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6153631A (en) 1996-10-23 2000-11-28 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
CA2219698C (en) 1996-10-31 2007-09-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
ATE346085T1 (en) 1996-12-06 2006-12-15 Vertex Pharma INHIBITORS OF THE INTERLEUKIN-1 BETA CONVERTING ENZYME
ATE233088T1 (en) 1996-12-20 2003-03-15 Takeda Chemical Industries Ltd METHOD FOR PREPARING A DELAYED RELEASE COMPOSITION
US6093737A (en) 1996-12-30 2000-07-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
PT950059E (en) 1997-01-06 2004-10-29 Pfizer CYCLIC SULFONA DERIVATIVES
JPH10206995A (en) 1997-01-21 1998-08-07 Konica Corp Silver halide photographic sensitive material
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
EA002594B1 (en) 1997-02-03 2002-06-27 Пфайзер Продактс Инк. Arylsulfonylamino hydroxamic acid derivatives
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
ATE271130T1 (en) 1997-02-07 2004-07-15 Univ Princeton MODIFIED PROTEIN KINASES THAT CAN USE MODIFIED NUCLEOTIDE TRIPHOSPHATE SUBSTRATES
JP3710489B2 (en) 1997-02-11 2005-10-26 ファイザー・インク Arylsulfonylhydroxamic acid derivatives
IL131582A0 (en) 1997-03-19 2001-01-28 Basf Ag Pyrrolo [2,3d] pyrimidines and their use as tyrosine kinase inhibitors
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
EP0983768A1 (en) 1997-05-23 2000-03-08 Nippon Shinyaku Co., Ltd. Medicinal composition for prevention or treatment of hepatopathy
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
EP1003720B1 (en) 1997-08-08 2004-03-31 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
DE69839887D1 (en) 1997-10-02 2008-09-25 Eisai R&D Man Co Ltd CONDENSED PYRIDINE DERIVATIVES
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
CA2309350C (en) 1997-11-12 2007-04-03 Mitsubishi Chemical Corporation Purine derivatives and medicaments comprising the same as active ingredient
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
US6191170B1 (en) 1998-01-13 2001-02-20 Tularik Inc. Benzenesulfonamides and benzamides as therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
JP2002505330A (en) 1998-03-04 2002-02-19 ブリストル−マイヤーズ スクイブ カンパニー Heterocyclo-substituted imidazopyrazine / protein tyrosine kinase inhibitors
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
JP4462654B2 (en) 1998-03-26 2010-05-12 ソニー株式会社 Video material selection device and video material selection method
US6127121A (en) 1998-04-03 2000-10-03 Epoch Pharmaceuticals, Inc. Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
US7715989B2 (en) 1998-04-03 2010-05-11 Elitech Holding B.V. Systems and methods for predicting oligonucleotide melting temperature (TmS)
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
PA8469401A1 (en) 1998-04-10 2000-05-24 Pfizer Prod Inc BICYCLE DERIVATIVES OF HYDROXAMIC ACID
PA8469501A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
KR19990085365A (en) 1998-05-16 1999-12-06 허영섭 Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof
JP2000072773A (en) 1998-08-28 2000-03-07 Zeria Pharmaceut Co Ltd Purine derivative
ES2253930T3 (en) 1998-09-18 2006-06-01 ABBOTT GMBH & CO. KG 4-AMINOPIRROLOPIRIMIDINAS AS QUINASA INHIBITORS.
US6362216B1 (en) 1998-10-27 2002-03-26 Array Biopharma Inc. Compounds which inhibit tryptase activity
ATE260255T1 (en) 1998-11-05 2004-03-15 Pfizer Prod Inc 5-OXO-PYRROLIDINE-2-CARBONIC ACID HYDROXAMIDE DERIVATIVES
ATE248170T1 (en) 1999-01-11 2003-09-15 Univ Princeton HIGH AFFINITY KINASE INHIBITORS FOR TARGET DETECTION AND THEIR USE
CZ27399A3 (en) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituted nitrogen heterocyclic derivatives process of their preparation, the derivatives employed as medicaments, pharmaceutical composition and a compound pharmaceutical preparation in which these derivatives are comprised as well as use of these derivatives for preparing medicaments
EP1157026A1 (en) 1999-02-22 2001-11-28 Boehringer Ingelheim Pharmaceuticals Inc. Polycyclo heterocyclic derivatives as antiinflammatory agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
KR100709497B1 (en) 1999-03-12 2007-04-20 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 Compounds useful as anti-inflammatory agents and method of making the same
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
SE515856C2 (en) 1999-05-19 2001-10-22 Ericsson Telefon Ab L M Carrier for electronic components
WO2000075139A2 (en) 1999-06-03 2000-12-14 Basf Aktiengesellschaft Benzothiazinone and benzoxazinone compounds
US6387894B1 (en) 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
PE20010306A1 (en) 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
GB9919588D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
US6559160B1 (en) 1999-08-27 2003-05-06 Chemocentryx, Inc. Compounds and methods for modulating cxcr3 function
US20070021493A1 (en) 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
ES2234662T3 (en) 1999-09-16 2005-07-01 Curis, Inc. HEDGEHOG SIGNALING ROUTE MEDIATORS, COMPOSITIONS AND USES RELATED TO THEMSELVES.
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
ATE247657T1 (en) 1999-09-17 2003-09-15 Basf Ag PYRAZOLOPYRIMIDINES AS MEDICINAL PRODUCTS
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
EP1222187B1 (en) 1999-10-06 2004-09-22 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
DE60025243T2 (en) 1999-10-12 2006-06-22 Takeda Pharmaceutical Co. Ltd. PYRIMIDIN-5-CARBOXIMIDE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
JP5420128B2 (en) 1999-10-13 2014-02-19 ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン Hedgehog pathway modulators and related compositions and methods of use
ATE324876T1 (en) 1999-10-14 2006-06-15 Curis Inc AGENTS OF ßHEDGEHOGß TRANSMITTING RAILWAYS, ASSOCIATED INTERLINGS AND USE
CA2286451A1 (en) 1999-10-14 2001-04-14 Grant A. Mitchell Hormone-sensitive lipase mediated male infertility
US6472153B1 (en) 1999-10-26 2002-10-29 Epoch Biosciences, Inc. Hybridization-triggered fluorescent detection of nucleic acids
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
US6660845B1 (en) 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
IL133809A0 (en) 1999-12-30 2001-04-30 Yeda Res & Dev Steroidal alkaloids and pharmaceutical compositions comprising them
GB0002032D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
FR2804958B1 (en) 2000-02-15 2005-07-08 Hoechst Marion Roussel Inc XANTHINE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US6613798B1 (en) 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
DK1272168T3 (en) 2000-03-30 2006-02-13 Curis Inc Sma organic molecules as cell proliferation regulators
US20020127625A1 (en) 2000-03-31 2002-09-12 Forskarpatent Is Syd Ab Methods of diagnosing immune related diseases
PT1939203E (en) 2000-04-25 2015-02-04 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6777439B2 (en) 2000-05-30 2004-08-17 Advanced Research & Technology Institute, Inc. Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
US6667398B2 (en) 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
NZ522839A (en) 2000-06-27 2004-11-26 Genelabs Tech Inc Novel compounds possessing antibacterial, antifungal or antitumor activity
US6534691B2 (en) 2000-07-18 2003-03-18 E. I. Du Pont De Nemours And Company Manufacturing process for α-olefins
AU2001292320A1 (en) 2000-10-02 2002-04-15 Tanabe Seiyaku Co., Ltd. Benzylamine compound, process for producing the same, and intermediate therefor
AU2002213467A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
AU2002213125B2 (en) 2000-10-11 2007-11-22 Applied Biosystems, Llc. Fluorescent nucleobase conjugates having anionic linkers
FR2815346B1 (en) 2000-10-13 2004-02-20 Servier Lab NOVEL AMINOTRIAZOLONE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
JP2002131859A (en) 2000-10-19 2002-05-09 Konica Corp Infrared sensitive silver halide photographic sensitive material for photographing and infrared sensitive silver halide emulsion
US6890747B2 (en) 2000-10-23 2005-05-10 Warner-Lambert Company Phosphoinositide 3-kinases
EA007538B1 (en) 2000-12-11 2006-10-27 Туларик Инк. Cxcr3 antagonists
US7157487B2 (en) 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
WO2002053160A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ivb
EP1359911A2 (en) 2000-12-29 2003-11-12 Alteon, Inc. Method for treating fibrotic diseases or other indications ivc
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
CN1267446C (en) 2001-01-22 2006-08-02 默克公司 Nucleoside derivatives as inhibitors of RNA-dependent PNA viral polymerase
GB0102239D0 (en) 2001-01-29 2001-03-14 Cancer Res Ventures Ltd Methods of chemical synthisis
PA8539401A1 (en) 2001-02-14 2002-10-28 Warner Lambert Co QUINAZOLINAS AS INHIBITORS OF MMP-13
PA8539501A1 (en) 2001-02-14 2002-09-30 Warner Lambert Co TRIAZOLO COMPOUNDS AS MMP INHIBITORS
MXPA03008560A (en) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Single-stage pfc + ballast control circuit/general purpose power converter.
WO2002088025A1 (en) 2001-04-26 2002-11-07 New York University Method for dissolving carbon nanotubes
DE60218458T2 (en) 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. ISOCHINOLINONE DERIVATIVES AS PARP INHIBITORS
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
JP2005505507A (en) 2001-06-13 2005-02-24 ジーンソフト ファーマシューティカルズ インコーポレイテッド Isoquinoline compounds having anti-infective activity
US20030236198A1 (en) 2001-06-13 2003-12-25 Genesoft, Inc. Antipathogenic benzamide compounds
CA2450628A1 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Benzothiophene compounds having antiinfective activity
US20030114467A1 (en) 2001-06-21 2003-06-19 Shakespeare William C. Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
DE10134721A1 (en) 2001-07-17 2003-02-06 Bayer Ag tetrahydroquinoxalines
EA007339B1 (en) 2001-07-27 2006-08-25 Кьюэрис, Инк. Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1414443B1 (en) 2001-08-01 2006-11-15 Merck & Co., Inc. BENZIMIDAZO 4,5-f|ISOQUINOLINONE DERIVATIVES
WO2003020880A2 (en) 2001-08-03 2003-03-13 Abbott Laboratories Method of identifying inhibitors of lck
ES2572030T3 (en) 2001-08-10 2017-07-19 Shionogi & Co., Ltd. Antiviral agent
JP2003073357A (en) 2001-09-03 2003-03-12 Mitsubishi Pharma Corp Rho KINASE INHIBITOR COMPRISING AMIDE COMPOUND
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2005538183A (en) 2001-09-13 2005-12-15 ジーンソフト ファーマシューティカルズ インコーポレイテッド Methods for treating infections caused by drug-resistant bacteria
AUPR769501A0 (en) 2001-09-14 2001-10-11 Biomolecular Research Institute Limited Cytokine receptor 1
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US7269663B2 (en) 2001-09-28 2007-09-11 Intel Corporation Tagging packets with a lookup key to facilitate usage of a unified packet forwarding cache
TWI330183B (en) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
CA2463822A1 (en) 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
WO2003041708A1 (en) 2001-11-09 2003-05-22 Boehringer Ingelheim Pharmaceuticals, Inc. Benzimidazoles useful as protein kinase inhibitors
DE10159269A1 (en) 2001-12-03 2003-06-18 Bayer Ag Arylation of olefins
DE10159270A1 (en) 2001-12-03 2003-06-12 Bayer Ag Process for the arylation of olefins
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
JP5082033B2 (en) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー LXR modulator
JP4085237B2 (en) 2001-12-21 2008-05-14 日本電気株式会社 Mobile phone usage contract system and communication method
BR0207583A (en) 2001-12-26 2004-04-27 Genelabs Tech Inc Polyamide derivatives having antibacterial, antifungal or antitumor activity
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
WO2003082341A1 (en) 2002-03-22 2003-10-09 Cellular Genomics, Inc. AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO[3,4-d] PYRIMIDINES AS KINASE MODULATORS
CA2480468C (en) 2002-03-26 2012-03-13 Biofrontera Discovery Gmbh Fredericamycin derivatives
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
DE10217046A1 (en) 2002-04-17 2003-11-06 Bioleads Gmbh Fredericamycin derivatives
EP1997494A3 (en) 2002-04-22 2009-06-10 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
EP1507535A1 (en) 2002-04-26 2005-02-23 Pfizer Products Inc. Pyrimidine-2,4,6-trione metallo-proteinase inhibitors
US6794562B2 (en) 2002-05-01 2004-09-21 Stine Seed Farm, Inc. Soybean cultivar 0332143
US20050203110A1 (en) 2002-05-23 2005-09-15 Coleman Paul J. Mitotic kinesin inhibitors
EP1556357A4 (en) 2002-06-14 2006-09-13 Cytokinetics Inc Compounds, compositions, and methods
CN1678311A (en) 2002-06-27 2005-10-05 诺沃挪第克公司 Aryl carbonyl derivatives as therapeutic agents
US7265111B2 (en) 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
MXPA05000130A (en) 2002-06-27 2005-02-17 Novo Nordisk As Aryl carbonyl derivatives as therapeutic agents.
DE10230917A1 (en) 2002-07-09 2004-02-05 Bioleads Gmbh Fredericamycin derivatives
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
BR0313460A (en) 2002-08-13 2005-07-05 Warner Lambert Co Naphthalene derivatives as matrix metalloproteinase inhibitors
EP1394159A1 (en) 2002-08-13 2004-03-03 Warner-Lambert Company LLC New thiophene derivatives, process for their preparation and pharmaceutical compositions containing them
JP4646626B2 (en) 2002-08-16 2011-03-09 アストラゼネカ アクチボラグ Inhibition of phosphoinositide 3-kinase β
EP1539180A4 (en) 2002-08-21 2006-08-30 Cytokinetics Inc Compounds, compositions, and methods
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
GB0220319D0 (en) 2002-09-02 2002-10-09 Cancer Res Campaign Tech Enzyme activated self-immolative nitrogen mustard drugs
JP4487774B2 (en) 2002-09-30 2010-06-23 萬有製薬株式会社 2-aminobenzimidazole derivatives
EP1549614A4 (en) 2002-10-03 2008-04-16 Targegen Inc Vasculostatic agents and methods of use thereof
US20050282814A1 (en) 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US20040146941A1 (en) 2002-11-04 2004-07-29 Biliang Zhang Chemical encoding technology for combinatorial synthesis
JP2004161716A (en) 2002-11-15 2004-06-10 Takeda Chem Ind Ltd Jnk inhibitor
WO2004046128A1 (en) 2002-11-21 2004-06-03 Vicore Pharma Ab New bicyclic angiotensin ii agonists
ATE496893T1 (en) 2002-12-20 2011-02-15 X Ceptor Therapeutics Inc ISOQUINOLINONE DERIVATIVES AND THEIR USE AS MEDICATIONS
US7365094B2 (en) 2002-12-23 2008-04-29 4Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7247736B2 (en) 2002-12-23 2007-07-24 4Sc Ag Method of identifying inhibitors of DHODH
US7071355B2 (en) 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
FR2850022B1 (en) 2003-01-22 2006-09-08 Centre Nat Rech Scient NOVEL USE OF MIFEPRISTONE AND ITS DERIVATIVES AS MODULATORS OF THE HEDGEHOG PROTEIN SIGNALING PATH AND ITS APPLICATIONS
WO2004075917A1 (en) 2003-02-28 2004-09-10 Toudai Tlo, Ltd. Organ or tissue fibrosis inhibitor
JP2006521373A (en) 2003-03-06 2006-09-21 デーエスエム アイピー アセッツ ベー. ヴェー. Method for preparing α-aminocarbonyl compound
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
EP1608317B1 (en) 2003-03-25 2012-09-26 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GB0306907D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
EP1644338A1 (en) 2003-04-01 2006-04-12 Aponetics AG 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
WO2004103270A2 (en) 2003-04-02 2004-12-02 Suntory Pharmaceutical Research Laboratories Llc Compounds and methods for treatment of thrombosis
WO2004089881A1 (en) 2003-04-14 2004-10-21 Astrazeneca Ab New sulfonyl derivatives of aminonaphtols
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1646615B1 (en) 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
WO2005002585A1 (en) 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
US20080118493A1 (en) 2003-07-15 2008-05-22 Beachy Philip A Elevated Hedgehog Pathway Activity In Digestive System Tumors, And Methods Of Treating Digestive Sytem Tumors Having Elevated Hedgehog Pathway Activity
GB0317951D0 (en) 2003-07-31 2003-09-03 Trigen Ltd Compounds
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014534A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
US20050124637A1 (en) 2003-08-15 2005-06-09 Irm Llc Compounds and compositions as inhibitors of receptor tyrosine kinase activity
US7390820B2 (en) 2003-08-25 2008-06-24 Amgen Inc. Substituted quinolinone derivatives and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005032343A2 (en) 2003-10-01 2005-04-14 The Johns Hopkins University Hedgehog signaling in prostate regeneration neoplasia and metastasis
US20080057071A1 (en) 2003-10-20 2008-03-06 Watkins David N Use Of Hedgehog Pathway Inhibitors In Small-Cell Lung Cancer
CA2545340A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
EP1689719A1 (en) 2003-11-25 2006-08-16 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
US7439254B2 (en) 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
AU2004308974A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
WO2005063766A2 (en) 2003-12-23 2005-07-14 Novartis Ag Bicyclic heterocyclic p-38 kinase inhibitors
CA2552664A1 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
US20050214310A1 (en) 2004-01-23 2005-09-29 Seattle Genetics, Inc. Melphalan prodrugs
KR20070039869A (en) 2004-02-03 2007-04-13 브루스 더블유. 스미스 Method of photolithography using a fluid and a system thereof
JP2007520559A (en) 2004-02-03 2007-07-26 アボット・ラボラトリーズ Aminobenzoxazoles as therapeutic agents
EP1717230B1 (en) 2004-02-13 2014-08-06 Msd K.K. Fused-ring 4-oxopyrimidine derivative
US20050187418A1 (en) 2004-02-19 2005-08-25 Small Brooke L. Olefin oligomerization
CA2556589A1 (en) 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
BRPI0508036A (en) 2004-02-27 2007-07-17 Hoffmann La Roche fused pyrazole derivatives
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
EP1571154A1 (en) 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Beta-aminoacid-derivatives as factor Xa inhibitors
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
PL1745041T3 (en) 2004-04-30 2012-11-30 Genentech Inc Quinoxaline inhibitors of the hedgehog signalling pathway
EP1740551B9 (en) 2004-04-30 2013-01-16 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
DE102004022897A1 (en) 2004-05-10 2005-12-08 Bayer Cropscience Ag Azinyl-imidazoazines
CA2566436C (en) 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
ES2605792T3 (en) 2004-05-13 2017-03-16 Icos Corporation Quinazolinone used as a human phosphatidylinositol 3-kinase delta inhibitor
EP1755609A1 (en) 2004-05-25 2007-02-28 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
EP1750715A1 (en) 2004-06-04 2007-02-14 Icos Corporation Methods for treating mast cell disorders
GB0413605D0 (en) 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
US7553838B2 (en) 2004-07-01 2009-06-30 Merck & Co. Inc. Mitotic kinesin inhibitors
US20060019967A1 (en) 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
WO2006015279A1 (en) 2004-07-28 2006-02-09 Neurogen Corporation Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
AU2005280112B2 (en) 2004-08-27 2012-07-19 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
CA2579002C (en) 2004-09-02 2012-11-27 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006038865A1 (en) 2004-10-01 2006-04-13 Betagenon Ab Nucleotide derivatives for the treatment of type 2 diabetes and other disorders
AU2005302279A1 (en) 2004-10-28 2006-05-11 Irm Llc Compounds and compositions as hedgehog pathway modulators
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
WO2006050501A2 (en) 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
CA2588607A1 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
BRPI0516915A (en) 2004-12-01 2008-03-11 Devgen Nv 5-carboxamido substituted thiazole derivatives which interact with ion channels, particularly with ion channels of the kv family
US20060156485A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
AU2006214190A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
US7579348B2 (en) 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
US20090124654A1 (en) 2005-03-01 2009-05-14 Mjalli Adnan M M Aryl and Heteroaryl Compounds, Compositions, Methods of Use
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
CN101184395A (en) 2005-04-06 2008-05-21 Irm责任有限公司 Diarylamine-containing compounds and compositions, and their use as modulators of steroid hormone nuclear receptors
KR100781704B1 (en) 2005-04-20 2007-12-03 에스케이케미칼주식회사 Novel pyridine derivatives, process for preparing thereof and pharmaceutical compositions containing them
JP2008538771A (en) 2005-04-25 2008-11-06 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー, アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック Use of compounds to improve telomerase processivity
CN100526315C (en) 2005-06-16 2009-08-12 浙江医药股份有限公司新昌制药厂 N2-quinoline or isoquinoline substituted purine derivative and its preparation method and uses
JP5275794B2 (en) 2005-06-22 2013-08-28 ケモセントリックス,インコーポレイティド Azaindazole compounds and methods of use
US7799795B2 (en) 2005-06-27 2010-09-21 Amgen Inc. Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders
JP2009500437A (en) 2005-07-11 2009-01-08 デブジェン エヌブイ Amide derivatives as kinase inhibitors
BRPI0615524A2 (en) 2005-07-11 2010-04-06 Devgen Nv amide derivatives as kinase inhibitors
WO2007029121A2 (en) 2005-07-21 2007-03-15 Galderma Research & Development Novel cyclopent-2-en-1-one derivatives which are ppar receptor modulators, and use thereof in pharmaceutical or cosmetic compositions
US20070017915A1 (en) 2005-07-22 2007-01-25 Weder Donald E Collapsible and/or erectable substantially egg-shaped container
EP1910347A2 (en) 2005-07-29 2008-04-16 Medivir Ab Macrocylic inhibitors of hepatitis c virus
GB0516723D0 (en) 2005-08-15 2005-09-21 Novartis Ag Organic compounds
AU2006283940A1 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 MAP kinase inhibitors and methods for using the same
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
WO2007025534A1 (en) 2005-09-01 2007-03-08 Bioagency Ag Fredericamycin derivatives
WO2007028022A2 (en) 2005-09-01 2007-03-08 Renovis, Inc. Novel compounds as p2x7 modulators and uses thereof
AR056544A1 (en) 2005-09-29 2007-10-10 Wyeth Corp PHENYLAMINOPROPANOL DERIVATIVES AND METHODS OF USE OF THE SAME
FR2892859B1 (en) 2005-10-27 2008-06-06 Commissariat Energie Atomique METHOD OF GRAFTING MOLECULES OF INTEREST ON INORGANIC SURFACES, SURFACES OBTAINED AND APPLICATIONS
US20090156611A1 (en) 2005-11-11 2009-06-18 Licentia Ltd. Mammalian hedgehog signaling modulators
DK1957461T3 (en) 2005-11-14 2016-12-19 Genentech Inc Bisamidhæmmere the hedgehog-signalling
EP1951724B1 (en) 2005-11-17 2011-04-27 OSI Pharmaceuticals, Inc. FUSED BICYCLIC mTOR INHIBITORS
WO2007062222A2 (en) 2005-11-22 2007-05-31 University Of South Florida Inhibition of cell proliferation
CA2629192A1 (en) 2005-11-22 2007-05-31 Merck & Co., Inc. Indole orexin receptor antagonists
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
WO2007075554A2 (en) 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
JP5512975B2 (en) 2005-12-29 2014-06-04 アッヴィ・インコーポレイテッド Protein kinase inhibitors
AU2006335174B2 (en) 2006-01-06 2012-09-06 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
US9540327B2 (en) 2006-01-13 2017-01-10 University Of Kentucky Research Foundation Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors
US20080058521A1 (en) 2006-01-26 2008-03-06 Wyeth Processes for the preparation of compounds
PE20071025A1 (en) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp TRISUSTITUTED AMINE COMPOUND
AU2007224020A1 (en) 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
DK2004683T3 (en) 2006-03-24 2016-08-22 Biogen Hemophilia Inc PC5 AS A FACTOR IX PROPEPTID PROCESSING ENZYM
EA200870385A1 (en) 2006-03-29 2009-04-28 Фолдркс Фармасьютикалз, Инк. INHIBITION OF TOXICITY ALPHA-SINUCLEINE
CA2647391C (en) 2006-04-04 2015-12-29 The Regents Of The University Of California Kinase antagonists
US7829590B2 (en) 2006-04-13 2010-11-09 Guy Brenchley Thiophene-carboxamides useful as inhibitors of protein kinases
CA2648196A1 (en) 2006-04-14 2007-10-25 Novartis Ag Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders
WO2007121453A2 (en) 2006-04-17 2007-10-25 The Regents Of The University Of California 2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents
GB0607948D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PT2322525E (en) 2006-04-21 2013-12-26 Novartis Ag Purine derivatives for use as adenosin a2a receptor agonists
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
JP2009536620A (en) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド Pharmaceutical combination
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
DE102006020327A1 (en) 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclic substituted, fused pyrazole derivatives and their use
UA93548C2 (en) 2006-05-05 2011-02-25 Айерем Елелсі Compounds and compositions as hedgehog pathway modulators
JP2009537621A (en) 2006-05-22 2009-10-29 アストラゼネカ アクチボラグ Indole derivatives
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
EP1859772B1 (en) 2006-05-24 2010-12-15 Guardant S.r.l. Alkalized local anesthetic in bag
GB0610317D0 (en) 2006-05-24 2006-07-05 Medical Res Council Antiparasitic compounds and compositions
CA2658462C (en) 2006-07-20 2011-09-27 Amgen Inc. Substituted pyridone compounds and methods of use
US20090258882A1 (en) 2006-07-28 2009-10-15 Novartis Ag 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors
US20100216791A1 (en) 2006-08-17 2010-08-26 Astrazeneca Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors
US8541428B2 (en) 2006-08-22 2013-09-24 Technion Research And Development Foundation Ltd. Heterocyclic derivatives, pharmaceutical compositions and methods of use thereof
US7678803B2 (en) 2006-08-24 2010-03-16 Serenex, Inc. Quinazoline derivatives for the treatment of cancer
AU2007289065B2 (en) 2006-09-01 2013-03-14 Senhwa Biosciences, Inc. Serine-threonine protein kinase and PARP modulators
WO2008025755A1 (en) 2006-09-01 2008-03-06 Basf Se Use of n-containing heterocycles in dermocosmetics
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
US7884180B2 (en) 2006-09-18 2011-02-08 Compugen Ltd Peptides which bind to G protein-coupled receptors
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
AU2007329678A1 (en) 2006-10-31 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Smoothened polypeptides and methods of use
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2669399A1 (en) 2006-11-13 2008-05-29 Eli Lilly & Co. Thienopyrimidinones for treatment of inflammatory disorders and cancers
WO2008063625A2 (en) 2006-11-20 2008-05-29 Adolor Corporation Pyridine compounds and methods of their use
CN101541793A (en) * 2006-11-20 2009-09-23 诺瓦提斯公司 Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
AU2007329548A1 (en) 2006-12-06 2008-06-12 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
AU2007332493A1 (en) 2006-12-14 2008-06-19 Daiichi Sankyo Company, Limited Imidazothiazole derivatives
EP2132178B1 (en) 2006-12-20 2015-08-19 Merck Sharp & Dohme Corp. Jnk inhibitors
WO2008079028A1 (en) 2006-12-22 2008-07-03 Industrial Research Limited Azetidine analogues of nucleosidase and phosphorylase inhibitors
JP5318779B2 (en) * 2006-12-27 2013-10-16 サノフイ Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
TWI433674B (en) 2006-12-28 2014-04-11 Infinity Discovery Inc Cyclopamine analogs
US20100056494A1 (en) 2007-01-26 2010-03-04 Irm Llc Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
WO2008103354A2 (en) 2007-02-20 2008-08-28 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
MX2009009429A (en) 2007-03-07 2010-07-05 Infinity Discovery Inc Cyclopamine lactam analogs and methods of use thereof.
EP2129677B1 (en) 2007-03-07 2014-12-17 Infinity Discovery, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
US8586619B2 (en) 2007-03-12 2013-11-19 Vm Therapeutics Llc Agents of calcium ion channel modulators
WO2008112913A1 (en) 2007-03-14 2008-09-18 Exelixis, Inc. Inhibitors of the hedgehog pathway
SG182205A1 (en) 2007-03-15 2012-07-30 Novartis Ag Organic compounds and their uses
MX2009009913A (en) 2007-03-23 2009-10-16 Amgen Inc Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer.
EP2139882B1 (en) 2007-03-23 2013-12-25 Amgen Inc. 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
UA98955C2 (en) 2007-03-23 2012-07-10 Амген Инк. Heterocyclic compounds and their uses
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
WO2008156513A2 (en) 2007-03-29 2008-12-24 University Of Connecticut Methods to protect skeletal muscle against injury
JP5412422B2 (en) 2007-04-13 2014-02-12 サノフイ Transition metal catalyzed synthesis of N-aminoindole
CN101636397B (en) 2007-04-13 2012-06-13 中国人民解放军军事医学科学院毒物药物研究所 Urea compounds, preparation methods and pharmaceutical uses thereof
WO2008131354A2 (en) 2007-04-20 2008-10-30 The Curators Of The University Of Missouri Phytoestrogens as regulators of hedgehog signaling and methods of their use in cancer treatment
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
JP2010163361A (en) 2007-04-27 2010-07-29 Dainippon Sumitomo Pharma Co Ltd Quinoline derivative
US7960353B2 (en) 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2008147852A1 (en) 2007-05-22 2008-12-04 Taigen Biotechnology Co., Ltd. Kinesin inhibitors
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8557823B2 (en) 2007-06-18 2013-10-15 Advanced Cancer Therapeutics, Llc Family of PFKFB3 inhibitors with anti-neoplastic activities
JP2010531304A (en) 2007-06-18 2010-09-24 ユニバーシティ オブ ルイビル リサーチ ファウンデーション、インコーポレイテッド PFKFB3 inhibitor family with antineoplastic activity
MX2009013869A (en) 2007-06-21 2010-03-17 Amgen Inc Process for making substituted 2-amino-thiazolones.
WO2009000412A1 (en) 2007-06-26 2008-12-31 Sanofi Aventis A regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles
WO2009004621A1 (en) 2007-07-02 2009-01-08 Technion Research & Development Foundation Ltd. Compositions, articles and methods comprising tspo ligands for preventing or reducing tobacco-associated damage
RU2345996C1 (en) 2007-07-17 2009-02-10 Андрей Александрович Иващенко Annelated azaheterocyclic amides, which include pyrimidine fragment, method of obtaining and their application
JP4846769B2 (en) 2007-07-30 2011-12-28 田辺三菱製薬株式会社 Pharmaceutical composition
JP4834699B2 (en) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 Pharmaceutical composition
WO2009042294A2 (en) 2007-08-10 2009-04-02 Burnham Institute For Medical Research Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
EP2185570B1 (en) 2007-08-13 2014-03-19 Metabasis Therapeutics, Inc. Novel activators of glucokinase
WO2009029617A1 (en) 2007-08-27 2009-03-05 Kalypsys, Inc. Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
WO2009044707A1 (en) 2007-10-03 2009-04-09 Riken Nitrotriazole derivative and method for producing compound using the same
BRPI0818426A2 (en) 2007-10-15 2017-06-13 Astrazeneca Ab combination product, use of a combination product, and method for treating cancer
GEP20125635B (en) 2007-11-13 2012-09-10 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
NZ586121A (en) 2007-12-13 2012-03-30 Siena Biotech Spa Benzimidazole derivatives as hedgehog pathway antagonists and therapeutic applications thereof
CA2708391A1 (en) 2007-12-13 2009-06-25 Sri International Ppar-delta ligands and methods of their use
WO2009081105A2 (en) 2007-12-21 2009-07-02 Ucb Pharma S.A. Quinoxaline and quinoline derivatives as kinase inhibitors
US7960397B2 (en) 2007-12-28 2011-06-14 Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions
US7894450B2 (en) 2007-12-31 2011-02-22 Nortel Network, Ltd. Implementation of VPNs over a link state protocol controlled ethernet network
US8193182B2 (en) * 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR101897881B1 (en) 2008-01-04 2018-09-12 인텔리카인, 엘엘씨 Certain chemical entities, compositions and methods
CN101938904A (en) 2008-01-09 2011-01-05 PGx健康有限责任公司 Intrathecal treatment of neuropathic pain with a2ar agonists
KR20100103455A (en) 2008-01-10 2010-09-27 아사히 가라스 가부시키가이샤 Glass, coating material for light-emitting device,and light-emitting device
DE102008004644A1 (en) 2008-01-16 2009-07-23 Robert Bosch Gmbh Monostatic multi-beam radar sensor device for a motor vehicle
CA2714516A1 (en) 2008-02-07 2009-08-13 Gilead Palo Alto, Inc. Abca-1 elevating compounds and the use thereof
EP2244709A4 (en) 2008-02-07 2012-02-29 Synta Pharmaceuticals Corp Topical formulations for the treatment of psoriasis
WO2009103022A1 (en) 2008-02-13 2009-08-20 Itherx Pharmaceuticals, Inc. Derivatives of substituted fused ring cycloindoles and methods of their use
TWI444384B (en) 2008-02-20 2014-07-11 Gilead Sciences Inc Nucleotide analogues and their use in the treatment of malignancies
US8673970B2 (en) 2008-02-21 2014-03-18 Sequoia Pharmaceuticals, Inc. HIV protease inhibitor and cytochrome p450 inhibitor combinations
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
JP2011515401A (en) 2008-03-20 2011-05-19 アムジエン・インコーポレーテツド Aurora kinase modulator and methods of use
WO2009118765A2 (en) 2008-03-28 2009-10-01 Panacea Biotec Limited Novel monoamine re-uptake inhibitor
WO2009146406A1 (en) 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
US20090312406A1 (en) 2008-06-12 2009-12-17 Hsing-Pang Hsieh Coumarin compounds and their use for treating viral infection
CN102066346A (en) 2008-06-20 2011-05-18 安美基公司 Process for making substituted 2-amino-thiazolones
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
CN102124009B (en) 2008-07-08 2014-07-23 因特利凯公司 Kinase inhibitors and methods of use
JP2011528368A (en) 2008-07-16 2011-11-17 シェーリング コーポレイション Bicyclic heterocyclic derivatives and their use as GPCR modulators
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
AU2009282480B2 (en) 2008-08-11 2015-05-07 Children's Medical Center Corporation Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
WO2010019921A2 (en) 2008-08-15 2010-02-18 The Regents Of The University Of California Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
MX2011002263A (en) 2008-09-10 2011-05-23 Kalypsys Inc Aminopyrimidine inhibitors of histamine receptors for the treatment of disease.
AU2009298877A1 (en) 2008-09-23 2010-04-08 Georgetown University Viral and fungal inhibitors
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010053998A1 (en) 2008-11-05 2010-05-14 Xenon Pharmaceuticals, Inc. Spiro-condensed indole derivatives as sodium channel inhibitors
CN104042618B (en) 2008-11-13 2018-02-16 吉利德卡利斯托加公司 The treatment of malignant hematologic disease
WO2010059593A1 (en) 2008-11-18 2010-05-27 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
AU2009322187B2 (en) 2008-12-04 2015-02-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of CNS disorders
JP2012512834A (en) 2008-12-19 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cyclic pyrimidine-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
US20110135655A1 (en) 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
US8173670B2 (en) 2009-01-13 2012-05-08 Van Andel Research Institute Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids
ES2598358T3 (en) 2009-02-13 2017-01-27 Ucb Pharma, S.A. Quinoline derivatives as PI3K kinase inhibitors
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
WO2010127212A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
JP5789252B2 (en) 2009-05-07 2015-10-07 インテリカイン, エルエルシー Heterocyclic compounds and uses thereof
EP2430013B1 (en) * 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
KR20120034666A (en) 2009-05-22 2012-04-12 엑셀리시스, 인코포레이티드 Benzoxazepines based p13k/mtor inthibitors against proliferative diseases
GB0908957D0 (en) 2009-05-22 2009-07-01 Ucb Pharma Sa Therapeutic agents
AU2010254200A1 (en) 2009-05-26 2011-12-08 Exelixis, Inc. Benzoxazepines as inhibitors of PI3K/m TOR and methods of their use and manufacture
SG182247A1 (en) 2009-05-27 2012-08-30 Hoffmann La Roche Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CA2761445A1 (en) 2009-05-27 2010-12-02 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CN101602768B (en) 2009-07-17 2012-05-30 河南省农科院农副产品加工研究所 Method for purifying sesamin and sesamolin
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
CN102741253A (en) 2009-09-29 2012-10-17 艾科睿控股公司 Pi3k (delta) selective inhibitors
US8106146B2 (en) 2009-10-06 2012-01-31 Medtronic, Inc. Therapeutic polymers and methods of generation
ES2520345T3 (en) 2009-11-12 2014-11-11 Ucb Pharma, S.A. Quinoline and quinoxaline derivatives as kinase inhibitors
WO2011058109A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
ES2442369T3 (en) 2009-11-12 2014-02-11 Ucb Pharma, S.A. Quinoline and quinoxaline derivatives as kinase inhibitors
WO2011060304A2 (en) 2009-11-13 2011-05-19 Constar International, Inc. Oxygen scavengers, compositions comprising the scavengers, and artcles made from the compositions
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
CA2781888C (en) 2009-12-11 2019-06-18 Nono Inc. Agents and methods for treating ischemic and other diseases
EP2513109A1 (en) 2009-12-18 2012-10-24 Amgen Inc. Heterocyclic compounds and their uses
SG10201502073PA (en) 2009-12-22 2015-05-28 Vertex Pharma Isoindolinone inhibitors of phosphatidylinositol 3-kinase
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US9260382B2 (en) 2010-02-16 2016-02-16 Uwm Research Foundation Methods of reducing virulence in bacteria
WO2011111880A1 (en) 2010-03-08 2011-09-15 주식회사 메디젠텍 Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3
CN102206172B (en) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 Substituted diaryl compound and preparation method and antiviral application thereof
EP2560656A4 (en) 2010-04-23 2013-11-27 Kineta Inc Anti-viral compounds
JP2013525368A (en) 2010-04-23 2013-06-20 キネタ・インコーポレイテツド Antiviral compounds
EP2566329B1 (en) 2010-05-04 2020-09-09 Alkermes Pharma Ireland Limited Process for synthesizing oxidized lactam compounds
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CN103038229B (en) 2010-05-26 2016-05-11 桑诺维恩药品公司 Heteroaryl compound and using method thereof
US20120149715A1 (en) 2010-05-28 2012-06-14 Yi Tsun Richard Kao Compounds and methods for the treatment of viral infections
EA031737B1 (en) 2010-06-03 2019-02-28 Фармасайкликс, Инк. USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (Btk) FOR TREATING LEUKEMIA AND LYMPHOMA
US20110306622A1 (en) 2010-06-11 2011-12-15 Calitoga Pharmaceuticals, Inc. Methods of treating hematological disorders with quinazolinone compounds in selected subjects
US9102617B2 (en) 2010-06-25 2015-08-11 Rutgers, The State University Of New Jersey Antimicrobial agents
BR112012033658A2 (en) 2010-07-05 2016-11-29 Merck Patent Gmbh bipyridyl derivatives useful for the treatment of kinase-induced diseases
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
AR082799A1 (en) 2010-09-08 2013-01-09 Ucb Pharma Sa DERIVATIVES OF QUINOLINE AND QUINOXALINE AS QUINASE INHIBITORS
AU2011302196B2 (en) 2010-09-14 2016-04-28 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
US8765773B2 (en) 2010-10-18 2014-07-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EP2630136A1 (en) 2010-10-21 2013-08-28 Universität des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
US20140031355A1 (en) 2010-11-04 2014-01-30 Amgen Inc. Heterocyclic compounds and their uses
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2640367A2 (en) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012068096A2 (en) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
CN103459384A (en) 2010-11-24 2013-12-18 埃克塞里艾克西斯公司 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture
WO2012071509A2 (en) 2010-11-24 2012-05-31 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8791107B2 (en) 2011-02-25 2014-07-29 Takeda Pharmaceutical Company Limited N-substituted oxazinopteridines and oxazinopteridinones
WO2012121953A1 (en) 2011-03-08 2012-09-13 The Trustees Of Columbia University In The City Of New York Methods and pharmaceutical compositions for treating lymphoid malignancy
AP2013007158A0 (en) 2011-03-11 2013-10-31 Gilead Calistoga Llc Combination therapies for hematologic malignancies
UY33957A (en) 2011-03-15 2012-10-31 Abbott Lab MODULATORS OF NUCLEAR HORMONE RECEPTORS
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102731492B (en) 2011-03-30 2016-06-29 江苏恒瑞医药股份有限公司 Cyclohexanes derivant, its preparation method and in application pharmaceutically
CN103635192B (en) 2011-04-01 2017-07-04 基因泰克公司 The combination of AKT inhibitor compounds and chemotherapeutics and application method
JO3733B1 (en) 2011-04-05 2021-01-31 Bayer Ip Gmbh Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines
KR101644051B1 (en) 2011-05-20 2016-08-01 삼성전자 주식회사 Optoelectronic device and laminated structure
JP5832647B2 (en) 2011-07-01 2015-12-16 ノバルティス アーゲー Combination therapy comprising a CDK4 / 6 inhibitor and a PI3K inhibitor for use in the treatment of cancer
CN103930422A (en) 2011-07-19 2014-07-16 无限药品股份有限公司 Heterocyclic compounds and uses thereof
JP6027611B2 (en) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ, インコーポレイテッド Heterocyclic compounds and uses thereof
PL2738156T3 (en) 2011-07-26 2018-06-29 Kbp Biosciences Usa Inc. 9-aminomethyl substituted tetracycline compounds
CN103635456B (en) 2011-07-26 2016-03-09 山东亨利医药科技有限责任公司 Tigecycline derivative
EP2741609A4 (en) 2011-08-12 2015-04-08 Salk Inst For Biological Studi Neuroprotective polyphenol analogs
AU2012302197B2 (en) 2011-08-29 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2012333092B2 (en) 2011-08-31 2016-04-21 Novartis Ag Synergistic combinations of PI3K- and MEK-inhibitors
WO2013044169A1 (en) 2011-09-21 2013-03-28 Nestec S.A. Methods for determining combination therapy with il-2 for the treatment of cancer
EA032463B1 (en) 2011-10-19 2019-05-31 Фармасайкликс Элэлси USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (Btk)
WO2013074583A1 (en) 2011-11-14 2013-05-23 The Broad Institute, Inc. Treatment and prognosis of lymphangioleiomyomatosis
WO2013086131A1 (en) 2011-12-06 2013-06-13 The Trustees Of The University Of Pennsylvania Inhibitors targeting drug-resistant influenza a
WO2013090725A1 (en) 2011-12-15 2013-06-20 Philadelphia Health & Education Corporation NOVEL PI3K p110 INHIBITORS AND METHODS OF USE THEREOF
US8772541B2 (en) 2011-12-15 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
TWI573792B (en) 2012-02-01 2017-03-11 歐陸斯迪公司 Novel therapeutic agents
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6427097B2 (en) 2012-06-15 2018-11-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. Compositions for treating cancer and methods for producing said compositions
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CA2880764C (en) 2012-08-03 2022-08-30 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
WO2014046617A1 (en) 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions and methods for treating cancer
US20140120060A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
US20140120083A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
RS58023B2 (en) 2012-11-01 2021-12-31 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US20150283142A1 (en) 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
RS60844B1 (en) 2012-11-02 2020-10-30 Tg Therapeutics Inc Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
JP6434416B2 (en) 2012-11-08 2018-12-05 ライゼン・ファーマシューティカルズ・エスアー Pharmaceutical composition comprising a PDE4 inhibitor and a PI3δ inhibitor or a dual PI3δ-γ kinase inhibitor
EP2920172B1 (en) 2012-11-16 2019-12-25 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
AU2014214561C1 (en) 2013-02-11 2019-01-17 Mitokinin, Inc. Compositions and methods for treating neurodegenerative diseases
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014141165A1 (en) 2013-03-15 2014-09-18 Universite De Geneve Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
BR112015025711A8 (en) 2013-04-08 2019-12-17 Janssen Pharmaceutica Nv use of ibrutinib and pharmaceutical composition comprising ibrutinib and an anticancer agent
JP6227889B2 (en) 2013-04-23 2017-11-08 関東化學株式会社 Novel organometallic complex and method for producing amine compound
AU2014273946B2 (en) 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
EP3632208A1 (en) 2013-06-13 2020-04-08 Biomatrica, INC. Cell stabilization
NZ714710A (en) 2013-06-14 2016-11-25 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
ES2855698T3 (en) 2013-06-20 2021-09-24 Taiho Pharmaceutical Co Ltd Method to predict the therapeutic efficacy of the PI3K / AKT / mTOR inhibitor based on the expression of PHLDA1 or PIK3C2B
UY35675A (en) 2013-07-24 2015-02-27 Novartis Ag SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
US20150065431A1 (en) 2013-08-27 2015-03-05 Northwestern University Reducing cutaneous scar formation and treating skin conditions
AU2014319921A1 (en) 2013-09-11 2016-03-17 Compugen Ltd. Anti-VSTM5 antibodies and the use thereof in therapy and diagnosis
WO2015051252A1 (en) 2013-10-03 2015-04-09 Duke University Compositions and methods for treating cancer with jak2 activity
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6466924B2 (en) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ, インコーポレイテッド Heterocyclic compounds and uses thereof
JP6626437B2 (en) 2013-10-08 2019-12-25 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. Combination of histone deacetylase inhibitor and either Her2 inhibitor or PI3K inhibitor
US20150105383A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma
US20150148345A1 (en) 2013-11-26 2015-05-28 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
CN105979948A (en) 2013-12-05 2016-09-28 安塞塔制药公司 Therapeutic combination of a pi3k inhibitor and a btk inhibitor
WO2015095840A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of cdk and erk inhibitors
WO2015095807A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
WO2015095819A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
EP4389225A2 (en) 2013-12-20 2024-06-26 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of type 2 mek and erk inhibitors
WO2015095834A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using erk1/2 and bcl-2 family inhibitors
WO2015095842A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
JP2017502016A (en) 2013-12-20 2017-01-19 バイオメッド バレー ディスカバリーズ,インコーポレイティド Treatment of cancer using a combination of a type 1 MEK inhibitor and an ERK inhibitor
WO2015095831A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of mtor and erk inhibitors
WO2015095829A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors
WO2015109286A1 (en) 2014-01-20 2015-07-23 Gilead Sciences, Inc. Therapies for treating cancers
DK3119397T3 (en) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of PI3K-gamma-mediated disorders
RU2016141267A (en) 2014-03-21 2018-04-24 Эббви Инк. ANTIBODIES AGAINST EGFR AND CONJUGATES ANTI-MEDICINAL PRODUCT
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US10632121B2 (en) 2014-05-16 2020-04-28 Memorial Sloan Kettering Cancer Center Platelet-derived growth factor receptor mutations and compositions and methods relating thereto
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
JP2017516799A (en) 2014-05-27 2017-06-22 アルミラル・ソシエダッド・アノニマAlmirall, S.A. Pharmaceutical use
EP3828265A1 (en) 2014-06-06 2021-06-02 Bluebird Bio, Inc. Improved t cell compositions
EP3200775B1 (en) 2014-10-03 2019-11-20 Novartis AG Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20180058741A (en) 2015-09-14 2018-06-01 인피니티 파마슈티칼스, 인코포레이티드 Solid form of isoquinolines, a process for their preparation, compositions comprising them and methods for using them

Also Published As

Publication number Publication date
TWI659956B (en) 2019-05-21
WO2012097000A1 (en) 2012-07-19
PH12018500960A1 (en) 2019-03-04
US20200385388A1 (en) 2020-12-10
EP3238722A1 (en) 2017-11-01
RU2013137424A (en) 2015-02-20
KR101875720B1 (en) 2018-07-09
PE20180318A1 (en) 2018-02-09
AU2012205669A1 (en) 2013-05-02
TW201700475A (en) 2017-01-01
JP6454672B2 (en) 2019-01-16
TW201247670A (en) 2012-12-01
EP3581574A1 (en) 2019-12-18
ES2637113T3 (en) 2017-10-10
JP2014501790A (en) 2014-01-23
CN103648499A (en) 2014-03-19
USRE46621E1 (en) 2017-12-05
DK2663309T3 (en) 2017-06-19
US9290497B2 (en) 2016-03-22
TWI674262B (en) 2019-10-11
ZA201305150B (en) 2014-09-25
JP2017061547A (en) 2017-03-30
EP2663309A4 (en) 2014-06-18
PE20141303A1 (en) 2014-10-01
NZ612909A (en) 2015-09-25
MX2013008065A (en) 2014-01-31
US20140371450A1 (en) 2014-12-18
TWI546305B (en) 2016-08-21
US9840505B2 (en) 2017-12-12
US10550122B2 (en) 2020-02-04
HK1245110B (en) 2020-04-24
EP3238722B1 (en) 2019-03-13
IL227387B (en) 2018-07-31
BR112013017670B1 (en) 2022-07-19
EP2663309A1 (en) 2013-11-20
CA2824197A1 (en) 2012-07-19
TW201906841A (en) 2019-02-16
CA2824197C (en) 2020-02-25
US20180273535A1 (en) 2018-09-27
RU2626883C2 (en) 2017-08-02
KR20140020249A (en) 2014-02-18
IL227387A0 (en) 2013-09-30
CL2013002007A1 (en) 2014-04-11
EP2663309B1 (en) 2017-03-15
BR112013017670A2 (en) 2017-08-15
AU2012205669B2 (en) 2015-08-20
US11312718B2 (en) 2022-04-26
CN103648499B (en) 2017-02-15
US20160152619A1 (en) 2016-06-02
US20120184568A1 (en) 2012-07-19
UA115767C2 (en) 2017-12-26
MX347708B (en) 2017-05-09
SG191897A1 (en) 2013-08-30
US8809349B2 (en) 2014-08-19
AR084824A1 (en) 2013-06-26
KR20180080358A (en) 2018-07-11
US20230108157A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
HK1245110B (en) Solid forms of isoquinolinones
HK1197068A1 (en) Methods for preparation of glycosphingolipids and uses thereof
GB2488674B (en) Catalyst and method of preparation
GB2505581B (en) Protective case and methods of making
PL2739293T3 (en) Methods and compositions for production of vaccina virus
EP2744331A4 (en) Methods and intermediates for preparing macrolactams
ZA201305972B (en) Method for the preparation of biphephos
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2747975A4 (en) An article of manufacture and method for its preparation
EP2718304A4 (en) Method of preparing ethylene- -olefin-diene copolymer
SG11201406623PA (en) Process for the preparation of rivaroxaban and intermediates thereof
IL227711A0 (en) Phenyl - isoxazol derivatives and preparation process thereof
EP2709999A4 (en) Quinazoline-7-ether compounds and methods of use
HK1207031A1 (en) Method of casting composite articles
EP2670245A4 (en) Alpha-ketoheterocycles and methods of making and using
IL237862A0 (en) Methods of reducing scalant formation
GB2509246B (en) Component and method of formation thereof
EP2684869A4 (en) Preparation of 3-mercaptopropionates
GB2516380B (en) Catalyst and method of preparation
GB201215942D0 (en) Method of treatent
EP2887938A4 (en) Methods of preparing tecovirimat
EP2861586A4 (en) Forms of vilazodone and processes for the preparation thereof
ZA201309732B (en) Process for the preparation of dexlansoprazole
GB201102364D0 (en) Lock means and method of use thereof
GB201102475D0 (en) Method of reducing offset